Nirogacestat dihydrobromide

N/A

Report date: 2026/05/09 20:00:18
NMEFirst In Class

Base Information

Drug NameNirogacestat dihydrobromide
Drug Alias NameNirogacestat hydrobromide奥格西韦奥NirogacestatPF-3084014 dihydrobromideOGSIVEO +[8] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionGamma-secretase inhibitors
TargetsGamma-secretase
Therapy Area/IndicationsMetastatic breast cancerSolid tumoursParaproteinemias +[16] 
Global Approved IndicationsFibromatosis, Aggressive
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited States
Original Approved Date2023/11/27
Country/TerritoryBelgiumCanadaUnited States +[23] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesPfizer Inc
China Registration ClassN/A

Develop Information

Active CompaniesDana-Farber Cancer InstituteGlaxosmithkline PlcMerck Europe Bv +[7] 
Inactive CompaniesJules Bordet InstitutePfizer IncThe University Of Texas MD Anderson Cancer Center
Active IndicationsParaproteinemiasBlood Protein DisordersCorneal Diseases +[10] 
Inactive IndicationsMetastatic breast cancerSolid tumoursPancreatic Neoplasms +[6] 

Other Information

ATC CodeN/A
Related LinksWikipediaDrugBankKEGG